A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses | Zendy

Hartmut J. Ehrlich | Zendy; Markus Müller | Zendy; Sandor Fritsch | Zendy; Markus Zeitlinger | Zendy; Greg Berezuk | Zendy; Alexandra LöwBaselli | Zendy; Maikel V. W. van der Velden | Zendy; Martin Bauer | Zendy; Friedrich Maritsch | Zendy; Borislava G. Pavlova | Zendy; Paul Anantharajah Tambyah | Zendy; Helen Oh | Zendy; Emanuele Montomoli | Zendy; Otfried Kistner | Zendy; Perry Barrett | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses

Author(s) -

Hartmut J. Ehrlich,

Markus Müller,

Sandor Fritsch,

Markus Zeitlinger,

Greg Berezuk,

Alexandra LöwBaselli,

Maikel V. W. van der Velden,

Martin Bauer,

Friedrich Maritsch,

Borislava G. Pavlova,

Paul Anantharajah Tambyah,

Helen Oh,

Emanuele Montomoli,

Otfried Kistner,

Perry Barrett

Publication year - 2009

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/605608

Subject(s) - vero cell , virology , biology , virus , microbiology and biotechnology

Novel strategies are required to provide rapid vaccine coverage in the event of an influenza pandemic. A phase I/II dose finding/formulation study was performed with a whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen) to evaluate safety and immunogenicity. Seventy-seven of 141 subjects in this study received a booster (12-17 months after priming) with a 7.5-microg dose of a clade 2.1 A/Indonesia vaccine. The prime-boost regimen resulted in antibody responses against clade 1, 2.1, 2.2, and 2.3 viruses that were significantly higher than those after the priming regimen. These findings demonstrate that a prime-boost regimen may alleviate vaccine supply constraints in a pandemic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research